Price
No data yet.
Social Signal Score
Revenue
$437.58M+5884.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gunilla Christina Osswald
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Beta
- -0.67
- Country
- SE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 35.33
Financials
Revenue
$437.58M+5884.5%Net Income
$212.39MEBITDA
$203.98MFree Cash Flow
$-166.00MEPS (diluted)
$2.39Shares Outstanding (diluted)
88.87M-0.3%Operating Expenses
$203.67MCash & Debt
$2.03BDividend per Share
$0.21Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.99B | $1.02B | $11.52 |
| 2024 | $257.35M | $-177.08M | $-2.00 |
| 2023 | $616.00M | $229.25M | $2.59 |
| 2022 | $228.29M | $-11.18M | $-0.13 |
| 2021 | $23.15M | $-119.79M | $-1.36 |
| 2020 | $62.35M | $-68.52M | $-0.78 |
| 2019 | $281.77M | $88.47M | $1.00 |
| 2018 | $713.97M | $381.60M | $4.33 |
| 2017 | $140.71M | $15.16M | $0.22 |
| 2016 | $105.61M | $57.58M | $0.65 |
| 2015 | $41.57M | $3.71M | $0.04 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BRCTF's reported EPS growth of 75.3% a year over 10 years. Historical EPS growth of 75% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $42.78
- Implied price
- $1,198
- Return from $31.78
- 106.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $595.49 — today's price is already 94.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| 20.0% | 78.3% | 85.0% | 90.8% | 95.9% | 100.6% |
| 25.0% | 85.8% | 92.7% | 98.7% | 104.1% | 108.9% |
| 30.0% | 93.2% | 100.4% | 106.7% | 112.2% | 117.3% |
| 35.0% | 100.6% | 108.1% | 114.6% | 120.4% | 125.7% |
| 40.0% | 108.1% | 115.8% | 122.5% | 128.6% | 134.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (2)
- Newsprnewswire.com·6h ago·Neutral
BioArctic and Mesenkia enter oncology research collaboration STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge. The collaboration comb
View source ↗ - Newsprnewswire.com·9h ago·Neutral
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00 a.m. CEST. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on August 26 at 9:30 a.m.
View source ↗
Earnings
Wed, Aug 26(in 6 days)
Consensus estimate $-0.03 per share
Typical surprise +43.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, May 20$0.25 vs $-0.03beat
- Wed, Feb 18$-0.01 vs $-0.06beat
- Thu, Nov 13$-0.10 vs $-0.12beat
- Mon, Jun 30$0.11 vs $0.16miss
- Mon, Mar 31$1.15 vs $1.03beat
- Tue, Dec 31$-0.03 vs $-0.06beat
Estimates and results for BRCTF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.